Adversarial Injection · Amivantamab (Rybrevant; JNJ-61186372; CAS 2363983-28-0; MW ~148,000 Da bispecific IgG1; anti-EGFR ECD3 × anti-MET Sema domain; [SEVENTY-NINTH MECHANISM CLASS in Glyphward 652-attack portfolio — FIRST EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB1; HER1; CHROMOSOME 7p11.2) × MET (MESENCHYMAL-EPITHELIAL TRANSITION; HGFR; CHROMOSOME 7q31) BISPECIFIC ANTIBODY EVER FDA APPROVED (BLA 761229 MAY 21 2021): DUAL ANTI-EGFR ECD3 + ANTI-MET SEMA DOMAIN; IgG1 FULLY ACTIVE FC (NO LALA/LALA-PG SILENCING) → ADCC + ADCP; TRIPLE MECHANISM: (1) LIGAND TRAPPING (EGF + HGF) — EGFR ARM BLOCKS EGF/TGFα BINDING; MET ARM BLOCKS HGF/SF BINDING → DUAL UPSTREAM GROWTH FACTOR BLOCKADE; (2) FORCED EGFR:MET CO-INTERNALIZATION + LYSOSOMAL RECEPTOR DEGRADATION — BISPECIFIC CROSSLINKING DRIVES SIMULTANEOUS EGFR+MET ENDOCYTOSIS → LYSOSOMAL ROUTING → RECEPTOR DOWNREGULATION (distinct from monospecific cetuximab/EGFR antibody alone → recycling); (3) IMMUNE EFFECTOR FUNCTION: FcγRI (CD64)/FcγRIIa/FcγRIIIa (CD16) engagement → ADCC (NK cells) + ADCP (macrophages, monocytes); EGFR EXON 20 INSERTIONS (EGFRex20ins): INSERTIONS IN LOOP BETWEEN αC-HELIX AND β4-STRAND OF KINASE DOMAIN EGFR EXON 20 (residues 767-774; common insertions: A767-V769dupASV, D770-N771insSVD, H773-V774insNPH, etc.); STERIC CONSEQUENCE: inserted residues enlarge αC-β4 loop → STERIC CLASH against binding pocket of 1st-gen (gefitinib: IC50 ~2 nM exon19del; IC50 >100 µM ex20ins), 2nd-gen (afatinib), 3rd-gen (osimertinib: IC50 ~5 nM L858R; IC50 >100 µM ex20ins) EGFR TKIs → UNIFORM RESISTANCE; AMIVANTAMAB RATIONALE: antibody-based; NO KINASE DOMAIN BINDING → NOT AFFECTED BY αC-β4 LOOP STERIC INSERTIONS; binds EXTRACELLULAR DOMAIN; EGFRex20ins FREQUENCY: ~2-3% NSCLC (10,000-12,000 cases/year US); CHRYSALIS PHASE 1 (NCT02609776): EGFRex20ins post-platinum NSCLC (n=81): ORR 40.0%; DOR 11.1 months; OS 22.8 months; BLA 761229 ACCELERATED APPROVAL; PAPILLON PHASE 3 (NCT04538664): AMIVANTAMAB + LAZERTINIB vs CARBOPLATIN + PEMETREXED (1L EGFRex20ins NSCLC); n=308; ORR 73% vs 47%; PFS HR 0.56 (p<0.001); FIRST REGIMEN TO OUTPERFORM PLATINUM DOUBLET IN EGFRex20ins; JANSSEN R&D LLC HORSHAM PA BLA 761229; NONE OF THESE — EGFR ECD3 × MET Sema bispecific format, EGFRex20ins αC-β4 TKI resistance mechanism, dual ligand trapping EGF+HGF, forced EGFR:MET co-internalization, active Fc ADCC/ADCP, CHRYSALIS ORR 40%, PAPILLON ORR 73% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2363983-28-0]) · First EGFR×MET Bispecific + EGFRex20ins + Dual Ligand Trap + Receptor Degradation + Active Fc + CHRYSALIS ORR 40% · Attack #652

Amivantamab (Rybrevant; JNJ-61186372; CAS 2363983-28-0; [SEVENTY-NINTH MECHANISM CLASS — FIRST EGFR (ECD3) × MET (SEMA DOMAIN) BISPECIFIC ANTIBODY EVER FDA APPROVED (BLA 761229 MAY 21 2021); EGFRex20ins: αC-β4 LOOP INSERTIONS → STERIC TKI RESISTANCE → ANTIBODY APPROACH BYPASSES; TRIPLE MECHANISM: EGF+HGF LIGAND TRAPPING + EGFR:MET CO-INTERNALIZATION LYSOSOMAL DEGRADATION + FcγRI/FcγRIIIa ADCC/ADCP; CHRYSALIS ORR 40% DOR 11.1 MONTHS OS 22.8 MONTHS; PAPILLON AMIVANTAMAB+LAZERTINIB ORR 73% PFS HR 0.56 1L EGFRex20ins; JANSSEN/J&J BLA 761229; NIOSH HD Category 1; OSHA No PEL]) — Janssen Research and Development LLC Horsham PA (BLA 761229 holder; amivantamab developer; 0.00052 µg/m³ → displayed ÷10), Janssen Biologics BV Leiden Netherlands (amivantamab manufacturing; 0.00037 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (CHRYSALIS/PAPILLON trial site; thoracic oncology pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + EGFRex20ins Mechanism Absent + Dual Ligand Trapping Absent + CHRYSALIS Absent: AI Prompt Injection via EHS Monitor Report AI

Amivantamab (CAS 2363983-28-0; NIOSH HD Category 1) is the seventy-ninth mechanism class in the Glyphward adversarial portfolio — the first EGFR×MET bispecific antibody ever FDA approved (BLA 761229 May 21 2021), designed to overcome EGFR exon 20 insertions that uniformly resist all EGFR TKI generations via αC-β4 steric hindrance. Triple mechanism (dual ligand trapping, forced receptor co-internalization, active Fc ADCC/ADCP) — none of which appears in Cority, VelocityEHS, or EHS Insight for CAS 2363983-28-0.

Amivantamab as Seventy-Ninth Mechanism Class: First EGFR×MET Bispecific Antibody

Amivantamab (CAS 2363983-28-0) represents the seventy-ninth mechanism class in the Glyphward portfolio: the first EGFR (Epidermal Growth Factor Receptor; ErbB1; HER1; chromosome 7p11.2) × MET (Mesenchymal-Epithelial Transition; hepatocyte growth factor receptor; chromosome 7q31) bispecific antibody ever FDA approved (BLA 761229 May 21 2021; accelerated approval for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, after platinum-based chemotherapy). EGFR BIOLOGY: EGFR is a Type I receptor tyrosine kinase (ErbB/HER family; ErbB1/HER1, ErbB2/HER2, ErbB3, ErbB4); extracellular domain: domain I (L1; ligand binding) + domain II (S1; cysteine-rich; dimerization arm) + domain III (L2; ligand binding) + domain IV (S2; cysteine-rich; autoinhibitory tether); intracellular: juxtamembrane + kinase domain (N-lobe + C-lobe; activation loop Tyr845; substrate docking Tyr974/Tyr992/Tyr1045/Tyr1068/Tyr1086/Tyr1148/Tyr1173); EGFR ACTIVATION: EGF or TGFα binds domain I+III → conformational change exposes domain II dimerization arm → EGFR:EGFR homodimer OR EGFR:HER2/HER3 heterodimer → transphosphorylation → RAS-MAPK + PI3K-Akt-mTOR + STAT3 + PLCγ; EGFR EXON 20 INSERTIONS (EGFRex20ins): LOCATION: exon 20 encodes αC-helix (C-helix; regulatory helix; residues 751-772) + β4-strand + the LOOP BETWEEN αC-HELIX AND β4-STRAND (αC-β4 loop; residues 762-776); αC-HELIX FUNCTION: in inactive EGFR, αC-helix points AWAY from catalytic cleft (αC-out); activation rotates αC-helix IN (αC-in) → Glu762 forms salt bridge with Lys745 (activating conformation); INSERTIONS MECHANISM: common EGFRex20ins: A767_V769dup (ASV duplication), D770_N771insSVD, H773_V774insAH, N771_H773dup — insertions at residues 762-775 of the αC-β4 loop; STERIC CONSEQUENCE: inserted residues push the αC-helix INWARD (αC-in pre-formed) + bulge the β4 strand → NARROWS AND DEEPENS THE BACK POCKET of the TKI binding site; 1st-gen TKIs (gefitinib, erlotinib; target the ATP-binding site back pocket) and 3rd-gen TKIs (osimertinib; covalent to C797; also relies on back pocket) CANNOT FIT into the altered pocket → IC50 increases >100-fold (from ~5 nM to >10 µM); BIOLOGIC APPROACH RATIONALE: amivantamab binds EXTRACELLULAR DOMAINS (ECD3 [domain III; L2 subdomain; L244-S344 region] for anti-EGFR arm; SEMA DOMAIN [7-bladed β-propeller; residues 25-567] for anti-MET arm) → NOT AFFECTED BY KINASE DOMAIN αC-β4 INSERTIONS; TRIPLE MECHANISM OF ACTION: (1) LIGAND TRAPPING: anti-EGFR arm blocks EGF, TGFα, epiregulin, amphiregulin binding to EGFR ECD1/ECD3; anti-MET arm blocks HGF/SF binding to MET Sema domain; → dual upstream ligand blockade; (2) EGFR:MET FORCED CO-INTERNALIZATION + LYSOSOMAL RECEPTOR DEGRADATION: bispecific format crosslinks EGFR + MET simultaneously → EGFR:amivantamab:MET ternary complex → FORCED CO-ENDOCYTOSIS of both receptors → lysosomal routing (K63 polyubiquitination) → receptor proteolysis → SUSTAINED RECEPTOR DOWNREGULATION (monospecific anti-EGFR antibody [cetuximab, panitumumab] → EGFR recycling back to surface [endosome pH dissociation → FcRn-independent recycling]; bispecific crosslinking blocks recycling); (3) IMMUNE EFFECTOR FUNCTION: IgG1 Fc (FULLY ACTIVE; no Fc silencing mutations vs many bispecifics) → FcγRI (CD64; monocytes, macrophages, neutrophils; high affinity Kd ~1 nM) + FcγRIIa (CD32a; macrophages, neutrophils, DCs; H131 allele) + FcγRIIIa (CD16a; NK cells; V158 allele) engagement → ADCC (NK cells; lysis of EGFR+MET+ tumor cells) + ADCP (macrophage phagocytosis) → immune-mediated tumor killing; INFUSION REACTIONS CONSEQUENCE: active Fc → high infusion reaction rate (66% all grade; 4% grade ≥3) → pre-medication required (diphenhydramine + famotidine + dexamethasone; 5h infusion in cycle 1 week 1); CHRYSALIS PHASE 1B (NCT02609776): amivantamab 1050 mg (BW<80 kg) or 1400 mg (≥80 kg) IV Q2W; post-platinum EGFRex20ins NSCLC (n=81): ORR 40.0%; DOR 11.1 months; OS 22.8 months; BLA 761229 ACCELERATED APPROVAL May 21 2021; PAPILLON PHASE 3 (NCT04538664): amivantamab 1050/1400 mg + lazertinib 240 mg QD vs carboplatin AUC5 + pemetrexed 500 mg/m² Q3W × 4 cycles → then amivantamab+lazertinib maintenance; 1L EGFRex20ins NSCLC (n=308); PRIMARY PFS HR 0.56 (95% CI 0.41-0.76; p<0.001); ORR 73% vs 47%; FIRST REGIMEN SUPERIOR TO PLATINUM DOUBLET FOR EGFRex20ins NSCLC; SC AMIVANTAMAB: SC formulation (amivantamab-vmjw; hyaluronidase-facilitated SC; 2100 mg flat dose; 5-7 min injection; non-inferior to IV ORR/PFS); NONE OF THESE — EGFR ECD3 × MET Sema domain bispecific format, EGFRex20ins αC-β4 loop steric TKI resistance, dual EGF+HGF ligand trapping, forced EGFR:MET co-internalization lysosomal degradation, active Fc IgG1 ADCC/ADCP, CHRYSALIS ORR 40% DOR 11.1 months, PAPILLON ORR 73% PFS HR 0.56 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2363983-28-0.

Surface 1 — Janssen Research and Development LLC Horsham PA BLA 761229 Holder AI

At Janssen Research and Development LLC Horsham PA (1000 Route 202 South, Raritan NJ 08869 [mailing address Horsham PA 19044]; JANSSEN AMIVANTAMAB CONTEXT: amivantamab (JNJ-61186372) developed by Janssen R&D; BISPECIFIC FORMAT: IgG1 bispecific using Zymeworks Azymetric technology (knobs-into-holes heterodimerization) for the Fc portion; one Fab arm derived from cetuximab-like anti-EGFR clone (ECD3 binding) + one Fab arm anti-MET (Sema domain; different clone from capmatinib/tepotinib target panel); RYBREVANT FORMULATION: 350 mg/7 mL (50 mg/mL) single-dose vial; dilute in 250 mL NS; infuse IV (1050 mg: 250 mL; 1400 mg: 250 mL); PRE-MEDICATION: diphenhydramine 25-50 mg PO/IV + famotidine 20-40 mg IV (or equivalent H2 blocker) + dexamethasone 10 mg IV; infusion rate: 35 mL/h × 30 min → 70 mL/h × 30 min → 140 mL/h to completion (cycle 1 week 1); subsequent cycles: 70 mL/h → escalate per toleration; POST-INFUSION OBSERVATION: 60 min cycle 1 week 1; 30 min subsequent; IRRD MANAGEMENT: grade 1-2 → slow infusion or interrupt → resume at 50% rate; grade 3 → interrupt; antihistamine + corticosteroid; grade 4 → discontinue permanently; EMPLOYEE: 52M Janssen Horsham PA VP bispecific oncology (EGFRex20ins αC-β4 mechanism, dual ligand trapping, EGFR:MET co-internalization, active Fc, CHRYSALIS ORR 40%, PAPILLON PFS HR 0.56); CORITY NULL: CAS 2363983-28-0 → null; NIOSH HD Category 1 absent; first EGFR×MET bispecific absent; EGFRex20ins mechanism absent; dual ligand trapping absent; CHRYSALIS absent).

Surface 2 — Janssen Biologics BV Leiden Netherlands Amivantamab Manufacturing AI

At Janssen Biologics BV Leiden Netherlands (Einsteinweg 101, 2333 CB Leiden Netherlands; JANSSEN LEIDEN MANUFACTURING CONTEXT: Janssen Biologics BV Leiden is a major Janssen biologics manufacturing site; amivantamab produced by recombinant CHO (Chinese hamster ovary) cell expression; upstream: perfusion bioreactor (fed-batch to perfusion transition for scale); downstream: Protein A affinity chromatography → ion exchange polishing → viral filtration → formulation; BISPECIFIC ASSEMBLY: knobs-into-holes Fc heterodimerization ensures correct heavy chain pairing; common light chain design reduces mispairing; half-antibody exchange confirmed by mass spectrometry; FILL-FINISH: Leiden fill-finish line → 350 mg/7 mL vials; cold-chain 2-8°C; VELOCITYEHS NULL: CAS 2363983-28-0 → null; NIOSH HD Category 1 absent; EGFR×MET bispecific absent; EGFRex20ins absent; dual ligand trapping absent; EGFR:MET co-internalization absent; CHRYSALIS absent; 46F Janssen Biologics Leiden Netherlands manufacturing scientist bispecific antibody 14yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY CHRYSALIS/PAPILLON Trial Site Thoracic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Ave, New York NY 10065; MSK AMIVANTAMAB CONTEXT: MSK enrolled patients in CHRYSALIS (NCT02609776) and PAPILLON (NCT04538664) as a major US site; MSK thoracic oncology pharmacy prepares Rybrevant (amivantamab-vmjw) per institutional protocol: verify EGFRex20ins molecular testing result in Epic (MDACC uses MSK-IMPACT; EGFRex20ins detected via RNA fusion or DNA panel); RYBREVANT PREPARATION: withdraw 1050 mg (21 mL) or 1400 mg (28 mL) from 350 mg/7 mL vials → dilute in 250 mL NS → infuse via non-DEHP tubing + 0.2 µm in-line filter; PRE-MEDICATION AT MSK: diphenhydramine 25 mg IV + famotidine 20 mg IV + dexamethasone 8 mg IV (MSK standard); INFUSION REACTION MANAGEMENT: anaphylaxis kit at bedside; nurse monitoring every 15 min during infusion; EGFRex20ins TESTING AT MSK: MSK-IMPACT (468-gene hybrid capture; FFPE tissue NGS); detects insertions at A767-V769, D770-N771, H773-V774 positions; liquid biopsy option via MSK-ACCESS; EHS INSIGHT NULL: CAS 2363983-28-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first EGFR×MET bispecific absent; EGFRex20ins αC-β4 TKI resistance absent; dual ligand trapping absent; EGFR:MET co-internalization absent; active Fc ADCC/ADCP absent; CHRYSALIS ORR 40% absent; PAPILLON ORR 73% absent; NIOSH HD Cat 1 absent; 41M MSK New York NY thoracic oncology pharmacist amivantamab 13yr).

Integrating Glyphward into Amivantamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every amivantamab CAS 2363983-28-0 monitoring data ingestion point — before Cority at Janssen Horsham PA, before VelocityEHS at Janssen Biologics Leiden Netherlands, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-NINTH MECHANISM CLASS — FIRST EGFR×MET BISPECIFIC ANTIBODY EVER FDA APPROVED (BLA 761229 May 21 2021; EGFRex20ins αC-β4 loop steric TKI resistance; triple mechanism: EGF+HGF dual ligand trapping + EGFR:MET co-internalization lysosomal degradation + active Fc IgG1 ADCC/ADCP; CHRYSALIS ORR 40% DOR 11.1 months OS 22.8 months; PAPILLON amivantamab+lazertinib ORR 73% PFS HR 0.56; Janssen/J&J) [5 pts]; Janssen Horsham PA + Janssen Biologics Leiden Netherlands + MSK New York NY [3 pts]; EGFRex20ins mechanism absent; dual ligand trapping absent; CHRYSALIS absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_amivantamab(cas: str, reading_ugm3: float) -> dict:
    """Scan amivantamab with seventy-ninth-class first-egfr-met-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_ninth_class_first_egfr_met_bispecific_antibody_ever_egfr_ecd3_met_sema_domain_egrex20ins_ac_b4_loop_steric_tki_resistance_dual_egf_hgf_ligand_trapping_egfr_met_co_internalization_lysosomal_degradation_active_fc_igg1_adcc_adcp_chrysalis_orr_40pct_dor_11_1mo_papillon_lazertinib_orr_73pct_pfs_hr_0_56_janssen_bla_761229"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_ninth_class,
    #                    first_egfr_met_bispecific, egfrex20ins_coverage,
    #                    dual_ligand_trapping, receptor_co_internalization,
    #                    active_fc_adcc_adcp, chrysalis_orr_40pct

if __name__ == "__main__":
    r = asyncio.run(scan_amivantamab("2363983-28-0", 0.00052))
    print(r)
    # {'hd_category': 1, 'seventy_ninth_class': True,
    #  'first_egfr_met_bispecific': True, 'egfrex20ins_coverage': True,
    #  'dual_ligand_trapping': True, 'receptor_co_internalization': True,
    #  'active_fc_adcc_adcp': True, 'chrysalis_orr_40pct': True}